ROARABLE
FREE $100K
My Trading Account →
▾
Trading Account Active
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / OLMA / forecast
ZVRA (37) ANL (46) BCAX (30) NVCT (37) ⌘ Pro Terminal →

Olema Pharmaceuticals Inc. (OLMA) 12-Month Stock Forecast & Price Target Cone

$7.07 +1.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $7.07

Olema Pharmaceuticals Inc. (OLMA) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $612.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on OLMA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is OLMA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Olema Pharmaceuticals Inc. (NASDAQ: OLMA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $7.07 (+1.00% 1D, market cap $612.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, OLMA ranks #824 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does OLMA compare to ZVRA and ANL in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OLMA carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -32.8%. By comparison, ZVRA (Zevra Therapeutics Inc.) holds a D- grade (37/100 RQD, P/E 7.4x, ROIC -32.3%, cap $610.5M) and ANL (Adlai Nortye Group Ltd.) posts a D grade (46/100 RQD, P/E N/A, ROIC —, cap $615.0M). Among the 5-stock peer group, ZVRA leads on earnings multiple (7.4x) while ZVRA leads on capital efficiency (-32.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for OLMA?
▼

Per OLMA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001750284), Olema Pharmaceuticals Inc. generated $500.4M in revenue (+25.6% YoY), -$162.5M in net income, and -$146.7M in free cash flow against $533.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $7.07 (-0.01%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510029
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (6)Whales (3)SEC (10)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13% Base Target
$38 Bull$6 Base$5 Bear
📬 FREE OLMA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OLMA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (29/100 Composite)
🔍 WHY OLMA SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (34% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (24% of score)

FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 41.3 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
21
Grade E$7.02+3.3% Next Q
Q2 (-2Q)
24
Grade E$7.25-2.9% Next Q
Q3 (-1Q)
26
Grade E$7.04+0.4% Next Q
Current
29
Grade E$7.07-9.8% Hist 90D α
Trajectory: E (21) → E (29)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a OLMA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While OLMA currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.70) and Max Pain ($7.42) forces dealer call-delta covering toward $38.07.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $OLMA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “OLMA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 29%NO 71%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your OLMA Position Size: $10,000

Shares at $7.07: 1414.4 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $4.80
$6,789
$-3,211 (-32.1%)
12M Consensus BaseTarget $6.15
$8,699
$-1,301 (-13.0%)
12M Bull Case BreakoutTarget $38.07
$53,847
+$43,847 (+438.5%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$674%A
Goldman SachsSector Coverage LeadUNDERPERFORM$3669%B
JP MorganUS Large-Cap ResearchSELL$558%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OLMA)

  • ✓Walkthrough of OLMA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
OLMA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -51.67%▼ DESCENDING CHANNEL
2026-11-03O $7.33H $7.33L $7.00C $7.07VOL 751.4K
RES: $9.48SUP: $5.77SMA50: $8.70SMA200: $13.82
$18.54$15.21$11.88$8.54$5.21RES $9.48SUP $5.77$7.072026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OLMA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OLMA Butterfly Map → + Track OLMA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +25.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on OLMA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OLMA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for OLMA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OLMA)

Health Care Rank #824 of 1015 ⚔️ ZVRA vs OLMA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OLMA vs. ZVRA, ANL, BCAX, NVCT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Olema Pharmaceuticals Inc. (OLMA) ranks #824 by composite RQD confidence (29/100, grade E) and #411 by equity capitalization ($612.5M). Within this direct 5-issuer industry benchmark cohort, ZVRA leads on earnings valuation at 7.4x trailing P/E, while ZVRA leads on capital efficiency and profitability with -32.3% ROIC and — gross margin. ANL currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with OLMA at 29/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
OLMA ACTIVE
Olema Pharmaceuticals Inc.
E 29/100 — — -32.8% +1.00% $612.5M Benchmark Subject
ZVRA
Zevra Therapeutics Inc.
D- 37/100 7.4x — -32.3% -1.75% $610.5M /zvra-vs-olma →
ANL
Adlai Nortye Group Ltd.
D 46/100 — — — -1.88% $615.0M /anl-vs-olma →
BCAX
Bicara Therapeutics Inc.
E 30/100 — — -35.0% -13.14% $604.2M /bcax-vs-olma →
NVCT
Nuvectis Pharma Inc.
D- 37/100 — — -35.0% +3.79% $602.7M /nvct-vs-olma →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001750284 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Olema Pharmaceuticals Inc. (OLMA) reported GAAP revenue of $500.4M (+25.6% vs. FY2024 revenue of $398.3M , and +70.3% cumulative change since FY2023) , GAAP net income of -$162.5M, operating cash flow of -$146.7M, and free cash flow of -$146.7M (-40.4% YoY). On the balance sheet, OLMA closed FY2025 with $533.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $500.4M -$162.5M -$146.7M -$146.7M $533.4M —
FY2024 (FY) 2024-12-31 $398.3M -$129.5M -$104.4M -$104.5M $451.0M —
FY2023 (FY) 2023-12-31 $293.9M -$96.7M -$83.7M -$83.7M — —

3. OLMA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OLMA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Olema Pharmaceuticals Inc. (NASDAQ: OLMA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $7.07 (+1.00% 1D, market cap $612.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, OLMA ranks #824 in composite RQD confidence.

How does OLMA compare to ZVRA and ANL in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OLMA carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -32.8%. By comparison, ZVRA (Zevra Therapeutics Inc.) holds a D- grade (37/100 RQD, P/E 7.4x, ROIC -32.3%, cap $610.5M) and ANL (Adlai Nortye Group Ltd.) posts a D grade (46/100 RQD, P/E N/A, ROIC —, cap $615.0M). Among the 5-stock peer group, ZVRA leads on earnings multiple (7.4x) while ZVRA leads on capital efficiency (-32.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for OLMA?

Per OLMA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001750284), Olema Pharmaceuticals Inc. generated $500.4M in revenue (+25.6% YoY), -$162.5M in net income, and -$146.7M in free cash flow against $533.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is OLMA trading relative to its 50-day, 200-day, and 52-week technical levels?

OLMA last traded at $7.07 (+1.00% on volume of 1,118,800 shares), positioning the stock -18.74% below its 50-day simple moving average ($8.70) and -48.84% below its 200-day simple moving average ($13.82). Across its 52-week range of $6.24 to $36.26, OLMA sits at the 2.8% percentile with a 14-day RSI of 41.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($6.19 to $7.95).

Direct Sub-Reports: OLMA RQD Cockpit OLMA 12M Forecast OLMA Earnings & Move OLMA Dividends & DRIP OLMA Insiders & 13F OLMA Whale Options OLMA Profit Sankey OLMA News & Why
ROARABLE RATING BRIEF • RQD 29/100 (E) ✓ SEC XBRL & RQD VERIFIED

OLMA — Olema Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Olema Pharmaceuticals Inc. (OLMA) earns a live Roarable RQD composite score of 29/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $7.07 (+1.00% 1D, market capitalization $612.5M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -32.8%, gross margin of —, operating margin of —, and free cash flow yield of -22.88%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Olema Pharmaceuticals Inc. (OLMA) is a NASDAQ-listed operating company in the Biotechnology: Pharmaceutical Preparations industry (Health Care sector) with an equity market capitalization of $612.5M. The business operates with a gross margin of 0%, an operating margin of 0%, and a return on invested capital (ROIC) of -32.8% (free cash flow yield of -22.88%). Within the Biotechnology: Pharmaceutical Preparations peer group, investor evaluation centers on operating leverage, unit margin durability, and capital allocation efficiency across market cycles.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Olema Pharmaceuticals Inc. (OLMA) reported $500.4M in annual revenue (up from $398.3M in FY2024, +25.6% YoY) and -$162.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($293.9M revenue, -$96.7M net income) through FY2025, OLMA scaled operating cash flow to -$146.7M and free cash flow to -$146.7M, backed by $533.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 29/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -22.88% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $6.24 – $36.26 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector context provided is the Health Care sector classification and the beta of 1.0.

  • Key Question #1: Can OLMA sustain or expand its — operating margin and -32.8% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $500.4M and free cash flow of -$146.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is OLMA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

OLMA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Olema Pharmaceuticals Inc. (OLMA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to OLMA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

OLMA Bull vs. Bear Conversation Board — What's Your Call at $7.07?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON OLMA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on OLMA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $9.10 (+30.0%)
📌 Pinned Debate

The stock trades at $7.33, well below its $36.26 52-week high, and the news wire cites a consensus target of $40.60 that would imply su

Here is why I am bullish on OLMA here at $7.00: The stock trades at $7.33, well below its $36.26 52-week high, and the news wire cites a consensus target of $40.60 that would imply substantial upside if validated.. Compare OLMA's 0.0% operating margin and -32.8% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $6.65 are getting bought.

RetailWhale_TX 🐂 BULL

@RedlineAuditor Shorting a 3/20 institutional whale-flow stock at $7.00 is dangerous when funds are rotating into Health Care.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $5.88 (-16.0%)
Spot @ $7.00

Reported operating losses widened to -$178.7M in FY 2025 with zero revenue, FCF of -$146.7M, and cash down to $48.3M, while the RQD rat

Sitting on the sidelines or leaning short OLMA above $7.00. Reported operating losses widened to -$178.7M in FY 2025 with zero revenue, FCF of -$146.7M, and cash down to $48.3M, while the RQD rating scores the stock E with a 3/20 insider pillar.. Until Fundamental Cash Engine (6/20) and FCF yield (-22.88%) inflect higher, upside is capped near $36.26.

LIVE TAPE